Cell Impact (CI) Q2 2026 earnings summary

Executive summary

• Net sales for Q2 2026 were SEK 1.4 million, a 32% decrease year-over-year, mainly due to the absence of raw material resales seen in Q2 2025.

• Operating loss (EBIT) improved to SEK -17.4 million from SEK -20.0 million year-over-year.

• Loss after financial items was SEK -17.7 million, compared to SEK -21.2 million in Q2 2025.

• The company secured a SEK 5.3 million order from a major US OEM and resolved on a rights issue of SEK 53.6 million, with bridge financing of SEK 15 million.

• Delayed customer transactions and prolonged lead times in the hydrogen market impacted liquidity and order timing.

Financial highlights

• Net sales for H1 2026 were SEK 3.6 million, down from SEK 4.1 million in H1 2025.

• Operating loss for H1 2026 was SEK -33.9 million, improved from SEK -40.8 million year-over-year.

• Cash flow from operating activities in Q2 2026 was SEK -2.4 million, a significant improvement from SEK -11.9 million in Q2 2025.

• Cash and cash equivalents at June 30, 2026, were SEK 0.4 million, rising to SEK 2.9 million by August 4, 2026.

• Debt/equity ratio at quarter-end was 75%, compared to 78% a year earlier.

Outlook and guidance

• The company expects more projects to approach continuous production, with several customer relationships nearing regular manufacturing and higher volumes.

• Market growth in hydrogen remains slower than anticipated, but customer interest and long-term plans remain intact.

• The company is focused on cost control, technological development, and preparing for increased commercial deliveries.